Organon (NYSE:OGN) and Sempre Health today announced a strategic
partnership designed to motivate eligible patients to refill their
prescriptions on time and improve adherence through an innovative
pricing program that offers personalized support.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231101900583/en/
The new program offered by Sempre Health and Organon will enable
eligible patients who refill their prescriptions on time and as
prescribed for Dulera™ (mometasone furoate, formoterol fumarate
dihydrate) and Asmanex™ (mometasone furoate), to receive discounts
on their medications throughout the course of their therapy, with
the aim of improving adherence to their medication.
Approximately 75% of patients in the United States struggle to
take their medicines as directed,i due to several factors including
prohibitive high costs and copayments for prescription
medicines,ii,iii managing multiple medications, complex treatment
regimensiv,v,vi or poor health literacy. Non-adherence to
medication presents a significant clinical and economic issue in
the United States with annual costs between $100 billion to $300
billion.vii,viii
“We are excited to include certain medicines from Organon’s
portfolio in Sempre’s program that is designed to enable
affordability and adherence," said Anurati Mathur, CEO of Sempre
Health. “Together, we hope to empower eligible patients who may not
otherwise adhere to their medication regimens to take better
control of their health and save money at the same time.”
Technology integrations, such as Sempre’s patented auto-refill
submission functionality, can help address the multiple and often
complex causes of non-adherence. Eligible patients receive
discounts at the point-of-sale, which increase as they remain on
therapy and continue to fill on-time, helping them fill their
medications and save money. The program also includes natural
language text message engagement, which leads to a personalized
experience for those enrolled.
“This partnership represents a significant step forward in
expanding access to medicines, and the ability to help eligible
patients adhere to their treatments while also saving money is a
winning combination,” said Ger Brennan, Vice President and
Commercial Lead, Established Brands at Organon. “The innovative
digital platform that Sempre Health provides is extremely exciting
and we are pleased to have our medications included as part of this
offering, ultimately making it easier for enrolled patients to
manage their health.”
According to a patient who has already enrolled in the program,
“This offering has meant the world to me. I did not take this
medication every day before. I used it sparingly, as I could not
afford to refill it every month. Now I’m able to better afford my
medication as prescribed.”
About Organon
Organon is a global healthcare company formed to focus on
improving the health of women throughout their lives. Organon
offers more than 60 medicines and products in women’s health in
addition to a growing biosimilars business and a large franchise of
established medicines across a range of therapeutic areas.
Organon’s existing products produce strong cash flows that support
investments in innovation and future growth opportunities in
women’s health and biosimilars. In addition, Organon is pursuing
opportunities to collaborate with biopharmaceutical innovators
looking to commercialize their products by leveraging its scale and
presence in fast growing international markets.
Organon has a global footprint with significant scale and
geographic reach, world-class commercial capabilities, and
approximately 10,000 employees with headquarters located in Jersey
City, New Jersey.
For more information, visit http://www.organon.com and connect
with us on LinkedIn, Instagram, Twitter and Facebook.
About Sempre Health
Sempre Health works with leading health plans and pharmaceutical
companies to reduce the cost of copayments for eligible patients
who refill their prescriptions on time. Based on several internally
and externally validated studies, Sempre Health boosts medication
adherence by greater than 20% and drives a 95 Net Promoter Score
across therapeutic classes and for enrolled patients in all 50
states. For more information visit: www.semprehealth.com.
Cautionary Note Regarding Forward-Looking Statements
Some statements and disclosures in this press release are
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements include all statements that do not
relate solely to historical or current facts and can be identified
by the use of words such as "may," “expects,” “intends,”
“anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,”
or words of similar meaning. These forward-looking statements
include statements regarding Organon’s expectations with respect to
its strategic partnership with Sempre Health. Such statements are
based on Organon’s current plans and expectations and are subject
to a number of risks and uncertainties that could cause Organon’s
plans and expectations, including actual results, to differ
materially from the forward-looking statements. Risks and
uncertainties include, but are not limited to, the possibility that
Organon’s strategic partnership with Sempre Health may not deliver
benefits to patients (including enabling affordability of and
adherence to medications) as expected. Organon undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially
from those described in the forward-looking statements can be found
in Organon’s filings with the Securities and Exchange Commission
("SEC"), including Organon’s Annual Report on Form 10-K for the
year ended December 31, 2022 and subsequent SEC filings, available
at the SEC’s Internet site (www.sec.gov).
i NCBI (National Center for Biotechnology Information) 2012.
Medication adherence: Helping patients take their medicines as
directed. Available from: URL: Medication Adherence: Helping
Patients Take Their Medicines As Directed - PMC (nih.gov). ii
Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et
al. The implications of choice: prescribing generic or preferred
pharmaceuticals improves medication adherence for chronic
conditions. Arch Intern Med. 2006;166:332–7. iii Goldman DP, Joyce
GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy
benefits and the use of drugs by the chronically ill. JAMA.
2004;291:2344–50. iv Chapman RH, Benner JS, Petrilla AA, Tierce JC,
Collins SR, Battleman DS, et al. Predictors of adherence with
antihypertensive and lipid-lowering therapy. Arch Intern Med.
2005;165:1147–52. v Iskedjian M, Einarson TR, MacKeigan LD, Shear
N, Addis A, Mittmann N, et al. Relationship between daily dose
frequency and adherence to antihypertensive pharmacotherapy:
evidence from a meta-analysis. Clin Ther. 2002;24:302–16. vi Wu JR,
Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients
who have heart failure: a review of the literature. Nurs Clin North
Am. 2008;43:133–53. vii–viii. vii IMS Institute for Healthcare
Informatics Avoidable costs in US health care. 2013. Available at:
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Institute/RUOM-2013/IHII_Responsible_Use_Medicines_2013.pdf.
Accessed October 17, 2023 viii Benjamin RM. Medication adherence:
Helping patients take their medicines as directed. Public Health
Rep. 2012;127(1):2–3.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101900583/en/
Media:
Organon: Karissa Peer (614) 314-8094
Kim Hamilton (908) 391-0131
Investor:
Jennifer Halchak (201) 275-2711
Alex Arzeno (646) 430-2028
Sempre Health: Michele Fox (781) 248-9455
Organon (NYSE:OGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Organon (NYSE:OGN)
Historical Stock Chart
From Sep 2023 to Sep 2024